Amendments to the Claims

Please amend Claims 1 and 3. The Claim Listing below will replace all prior versions of the Claims in the application:

Claim Listing

- 1. (Currently amended) A pharmaceutical composition comprising a unit dosage form of an effective amount of a polydiallylamine homopolymer, said homopolymer characterized in that the polymer is substantially free of alkylated amine monomers and a pharmaceutically acceptable carrier.
- 2. (Original) The pharmaceutical composition of Claim 1 wherein said homopolymer is crosslinked by means of a multifunctional crosslinking agent, and said crosslinking agent is present in an amount from about 2.5-20% by weight, based upon the combined weight of monomer and crosslinking agent.
- 3. (Currently amended) The pharmaceutical composition of Claim 2 wherein <u>the polymer is</u> crosslinked using epichlorohydrin said crosslinking agent comprises epichlorohydrin.
- 4. (Original) The pharmaceutical composition of Claim 1 wherein the polydiallylamine homopolymer is characterized by one or more monomeric units of the formulae:

or a combination thereof and salts thereof.

- 5. (Original) The pharmaceutical composition of Claim 4 wherein the monomeric units are in the free-base form.
- 6. (Original) The pharmaceutical composition of Claim 4 wherein the monomeric units are a salt or a partial salt.
- 7. (Previously presented) A pharmaceutical composition of Claim 1 wherein the unit dosage form is a tablet.
- 8. (Previously presented) A pharmaceutical composition of Claim 1 wherein the unit dosage form is a capsule.